ALLURION TECHNOLOGIES, INC. 8-K

What Happened
Allurion Technologies, Inc. (ticker: ALUR) announced on March 12, 2026 that the New York Stock Exchange notified the company on March 6, 2026 it would commence proceedings to delist Allurion’s common stock and warrants for failure to meet NYSE Rule 802.01B (minimum average global market capitalization). Trading in the common stock on the NYSE was suspended after market close on March 6, 2026. The company has appealed the delisting determination.

Key Details

• NYSE cited non-compliance with Rule 802.01B, which requires a minimum average global market capitalization of $15 million over 30 consecutive trading days.
• If the appeal fails, the NYSE is expected to file Form 25 with the SEC; delisting would occur on the 10th day after that filing.
• Following the suspension, Allurion’s securities are trading on the OTCID Market; the company intends to apply to a higher-tier OTC Market under symbols "ALUR" and "ALUR.WS".
• The filing references a March 12, 2026 press release (Exhibit 99.1) noting management’s plan—after recent FDA approval of the Allurion Gastric Balloon System/Allurion Smart Capsule—to regain listing compliance or relist on NYSE American, strengthen the balance sheet, and fund U.S. commercialization.

Why It Matters
A delisting and move to the OTC market can reduce liquidity, widen bid-ask spreads, and limit visibility among institutional investors, which may affect trading volume and share price volatility. Allurion’s appeal and stated plan to regain compliance or relist are material to investors because they affect where and how the stock trades and the company’s access to capital markets while it commercializes its FDA-approved product. The company also warns there is no assurance the OTC trading will remain active or that brokers will provide continuous quotes.